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BACKGROUND: Practice guidelines support an early invasive strat-
egy in patients with non-ST segment elevation acute coronary syn-
dromes, particularly in those at higher risk.
OBJECTIVES: To compare North American rates of invasive car-
diac procedure use stratified by risk.
METHODS: Use of invasive cardiac procedures and other care pat-
terns in patients with non-ST segment elevation acute coronary syn-
dromes from the United States (US) Can Rapid risk stratification of
Unstable angina patients Suppress ADverse outcomes with Early
implementation of the ACC/AHA guidelines (CRUSADE) National
Quality Improvement Initiative (n=88,097; 465 hospitals) and
Canadian ACS Registries I (n=1270; 51 hospitals) and II (n=1473;
36 hospitals) were compared after dividing patients into different risk
categories based on predicted risk of in-hospital mortality.
RESULTS: While the overall use of invasive procedures was higher
in the US, high-risk patients were least likely to undergo coronary
angiography (41% versus 64% in Canada [P<0.0001] and 53% versus
76% in the United States [P<0.0001]) and percutaneous coronary
intervention (14% versus 32% in Canada [P<0.0001] and 28% versus
51% in the US [P<0.0001]) compared with low-risk patients in both
countries, and had longer median waiting times for these procedures
(120 h versus 96 h in Canada [P<0.0001] and 34 h versus 23 h in the
US [P<0.0001] for coronary angiography).
CONCLUSIONS: The inverse relationship between risk level and
the use of invasive cardiac procedures for patients in the US and
Canada suggests that a risk stratification-guided approach for triaging
patients to an early invasive management strategy is paradoxically
used. This incongruous relationship holds true regardless of resource
availability or overall rates of cardiac catheterization.
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Le recours paradoxal aux interventions
cardiaques effractives pour des patients
souffrant d’un infarctus du myocarde sans
élévation du segment ST : La perspective
internationale de l’initiative CRUSADE et des
registres canadiens de SCA I et II
HISTORIQUE : Les directives cliniques étayent une stratégie effractive
précoce chez les patients atteints d’un syndrome coronarien aigu sans
élévation du segment ST, notamment chez les personnes les plus vulnérables.
OBJECTIFS : Comparer les taux nord-américains de recours aux
interventions cardiaques effractives, stratifiées selon le risque.
MÉTHODOLOGIE : Les auteurs ont comparé le recours aux interventions
cardiaques effractives et d’autres modes de soins chez les patients atteints de
syndromes coronariens aigus sans élévation du segment ST participant à
l’initiative nationale d’amélioration de la qualité (n=88 097, 465 hôpitaux)
CRUSADE des États-Unis – pour établir si la stratification rapide du risque
des patients atteints d’angine instable peut supprimer les issues négatives
lorsqu’elle s’accompagne de l’implantation précoce des lignes directrices de
l’ACC et de l’AHA – au recours à ces interventions selon les registres
canadiens de SCA I (n=1 270, 51 hôpitaux) et II (n=1 473, 36 hôpitaux)
d’après le risque prévu de mortalité en milieu hospitalier.
RÉSULTATS : Le recours global aux interventions effractives était plus
élevé aux États-Unis, mais les patients à haut risque étaient les moins
susceptibles de subir une coronarographie (41 % par rapport à 64 % au
Canada [p < 0,0001] et 53 % par rapport à 76 % aux États-Unis
[p < 0,0001]) et une intervention coronaire percutanée (14 % par rapport à
32 % au Canada [p < 0,0001] et 28 % par rapport à 51 % aux États-Unis
[p < 0,0001]) par rapport aux patients à faible risque dans les deux pays, et
leur temps médian d’attente était plus long pour ces interventions
(120 heures par rapport à 96 heures au Canada [p < 0,0001] et 34 heures par
rapport à 23 heures aux États-Unis [p < 0,0001] pour la coronarographie).
CONCLUSIONS : La relation inversement proportionnelle entre le taux
de risque et le recours aux interventions cardiaques effractives des patients
des États-Unis et du Canada laisse supposer l’utilisation paradoxale d’une
démarche orientée par la stratification du risque au moment du triage des
patients en vue d’une prise en charge effractive précoce. Cette relation
incongrue demeure, quelle que soit la disponibilité des ressources ou le
taux global de cathétérisme cardiaque.
Acute coronary syndromes continue to be one of the majorcauses of morbidity and mortality in North America (1).
There is mounting evidence suggesting that an early invasive strat-
egy for treating patients with high-risk non-ST segment elevation
acute coronary syndromes (NSTE ACS) is associated with reduced
morbidity and mortality (2-6). Practice guidelines for the manage-
ment of patients with unstable angina or non-ST segment eleva-
tion myocardial infarction (NSTEMI), the two conditions that
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collectively make up NSTE ACS, were jointly published by the
American College of Cardiology (ACC) and the American Heart
Association (AHA) in September 2000 (7), and were subsequently
updated with new evidence in March 2002 (8). The ACC/AHA
guidelines give a class IA recommendation for early invasive treat-
ment for patients with high-risk features such as elevated cardiac
markers, ischemic electrocardiogram (ECG) changes, recurrent
ischemia, signs of heart failure and signs of hemodynamic instabil-
ity. Similar recommendations have been made regarding the risk
stratification and management of NSTE ACS patients in Canada
(9-11). However, recent studies have suggested that early invasive
management strategies are selectively targeted for lower-risk
patients in the United States (US) and Canada (12,13).
Multiple prior studies have demonstrated that patients with
STEMI and NSTE ACS in the US are more likely to undergo car-
diac catheterization and revascularization than in Canada, per-
haps due to differences in the availability of facilities for
performing invasive cardiac procedures between the US and
Canada (14-21). However, these studies did not evaluate how risk
stratification influenced triage decisions for the use of invasive
cardiac procedures and other care processes.
Thus, we analyzed contemporary care patterns for patients with
NSTE ACS in both the US and Canada to determine how patient
risk status influenced the use of medications and invasive proce-
dures recommended by practice guidelines in the two countries.
METHODS
Study descriptions
The Can Rapid risk stratification of Unstable angina patients
Suppress ADverse outcomes with Early implementation of the
ACC/AHA guidelines (CRUSADE) National Quality
Improvement Initiative is an ongoing quality improvement pro-
gram that collects data on high-risk NSTE ACS patients from
over 400 participating centres in the US. The institutional review
board of each site approved participation in CRUSADE, and
because data were collected only during initial hospitalization in
an anonymous fashion, informed consent was waived. Patients in
CRUSADE presented with acute ischemic symptoms (lasting
10 min or longer) at rest within 24 h before hospital arrival and
had at least one of the following high-risk features: ST segment
depression of 0.5 mm or greater, transient ST segment elevation of
0.5 mm to 1.0 mm (lasting for less than 10 min) or positive cardiac
markers (elevated troponin I or T and/or creatine kinase [muscle-
brain] greater than the upper limit of normal for the local labora-
tory assay used at each institution).
Details of the Canadian ACS Registry I were reported else-
where (22). The registry included 5312 patients from 51 hospitals
in nine provinces in Canada between September 1999 and June
2001 if they were 18 years of age or older, admitted to hospital
with a suspected ACS (defined by symptoms consistent with
acute cardiac ischemia within 24 h of onset), and if the qualify-
ing ACS was not deemed to have been precipitated by a signifi-
cant comorbidity such as trauma or gastrointestinal bleeding.
The Canadian ACS Registry I contained patients with unstable
angina, NSTEMI and STEMI, but did not require specific
ischemic ECG changes for the inclusion of patients with unstable
angina. The Canadian ACS Registry II focused specifically on
NSTE ACS. It included 2356 patients from 36 hospitals in seven
provinces in Canada between January and December 2003 if they
were: 18 years of age or older, diagnosed with NSTE ACS as
defined by symptoms thought to be consistent with acute cardiac
ischemia within 24 h of symptom onset, and the qualifying ACS
must not have been precipitated or accompanied by a significant
comorbidity (eg, trauma, gastrointestinal bleeding, perioperative
or periprocedural myocardial infraction). Likewise, specific
ischemic ECG changes were not required for inclusion of patients
with unstable angina. In both Canadian ACS registries, the local
hospital research ethics board approved the study, and all patients
who were followed after discharge provided informed consent.
Data collection
In all studies, a standardized case report form was used by the des-
ignated physician or study coordinator to record demographic and
clinical characteristics, medical history, selected laboratory results,
ECG findings, use of cardiac medications, in-hospital procedures,
and cardiovascular events and outcomes. In the case of the
Canadian ACS Registries I and II, the case report form was for-
warded to the coordinating centre (the Canadian Heart Research
Centre) and scanned directly into an electronic database
(TeleForm, Version 7.0, Cardiff, USA). Data checks were per-
formed centrally to ensure accuracy, and for key variables, sites
were queried and corrected or clarified in case of missing or incom-
plete data. Details regarding data collection for CRUSADE and a
description of the data collection form have been previously pub-
lished (23). In brief, data collected included clinical characteris-
tics, the use of acute medications (within 24 h of hospital arrival),
the use and timing of invasive cardiac procedures, laboratory
results, clinical outcomes, and discharge therapies and interven-
tions. Data collection did not continue after hospital transfer due
to current privacy regulations, which prohibit collection of anony-
mous data after hospital transfer. Any contraindications to
guideline-recommended therapies were also recorded.
Analysis population
Patients with NSTE ACS (both unstable angina and NSTEMI)
from CRUSADE and patients with NSTEMI from the Canadian
ACS Registries I and II were analyzed, because patients with
unstable angina in the Canadian registries did not require
ischemic ECG changes for inclusion (as was required in
CRUSADE). NSTE ACS patients in CRUSADE (n=88,097)
who were treated at 465 hospitals (90% with onsite cardiac
catheterization) in 45 US states from January 2001 through
December 2003 were analyzed. Within the Canadian ACS
Registry I, 1270 of 5312 patients had NSTEMI, while 1473 of
2356 patients had NSTEMI in the Canadian ACS Registry II.
Thus, a total of 2743 patients with NSTEMI were included from
both Canadian ACS registries. Of the 51 and 36 hospitals partici-
pating in the Canadian ACS Registries I and II, respectively, 29%
and 33% had onsite cardiac catheterization. In a secondary analy-
sis, the patient population was restricted to patients presenting to
hospitals with onsite cardiac catheterization facilities. 
Statistical analysis
Categorical variables are presented as frequencies or percentages,
and continuous variables as medians with 25th and 75th per-
centiles. The Platelet glycoprotein IIb-IIIa in Unstable angina:
Receptor Suppression Using Integrilin Therapy (PURSUIT) mor-
tality risk model for unstable angina/NSTEMI was used in the
present study, and was adapted from the original model that was
developed to predict 30-day mortality to, in turn, predict the risk
of in-hospital mortality (24). Variables included in this model are
age, sex, signs of congestive heart failure on presentation, admis-
sion heart rate, admission systolic blood pressure, ST depression
and elevated cardiac markers. The original PURSUIT population
was divided into tertiles of patients (low-risk, moderate-risk and
high-risk) based on the predicted risk of in-hospital mortality for
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each patient. The ranges of in-hospital mortality rates within each
risk tertile were used to establish low-risk, moderate-risk and high-
risk categories for predicted in-hospital mortality rates for patients
in the present analysis population.
Baseline characteristics, use of guideline-recommended acute
(less than 24 h) medications, use and timing of invasive cardiac
procedures, and in-hospital clinical outcomes were compared
among the three risk groups separately in the US and Canadian
populations. Comparisons between patient risk groups were
made using the χ2 test for categorical variables and the Kruskal-
Wallis test for continuous variables. The logistic generalized esti-
mating equations and ordinary logistic regression methods were
used to obtain the unadjusted OR for treatments and in-hospital
outcomes by risk groups. The generalized estimating equations
method produces estimates similar to those from ordinary logis-
tic regression, but the estimated variances are adjusted for
within-hospital clustering of responses, because patients admit-
ted in the same hospital tend to be more similar to each other
than to those in different hospitals (25). Direct comparisons
were not made between the US and Canadian populations.
Statistical analyses were performed by the Canadian Heart
Research Centre and the Duke Clinical Research Institute using
the SAS software package version 8.2 (SAS Institute, USA).




Among the 88,097 US patients in CRUSADE, 3814 patients were
excluded due to missing data that precluded the classification of
risk status. Among the 2743 Canadian patients with NSTEMI in
the ACS Registries I and II, 44 patients were excluded due to
missing data.
In the analyzable population of 84,283 US patients from
CRUSADE, 50.0% of patients were classified as high-risk based
on predicted in-hospital mortality rates, 24.3% were classified as
moderate-risk and 22.7% were classified as low-risk. Among the
2699 Canadian patients in the analyzable population, 39.7% were
classified as high-risk, 28.3% were classified as moderate-risk and
32.0% were classified as low-risk.
Baseline clinical characteristics stratified by risk are shown in
Table 1. In both Canada and the US, patients in the high-risk
groups were older, less commonly male, more likely to present
with ST segment depression, and more likely to have signs of heart
failure on presentation, renal insufficiency, diabetes mellitus, prior
myocardial infarction, prior stroke and prior coronary artery
bypass grafting surgery than patients in the moderate-risk and low-
risk groups.
Acute medications
In the Canadian and the US populations, high-risk patients were
least likely to have received acute (less than 24 h) acetylsalicylic
acid, clopidogrel or ticlopidine, glycoprotein IIb/IIIa inhibitors
and heparin than patients in the low- and moderate-risk groups
(Tables 2 and 3). Patients in the US more commonly received
clopidogrel and glycoprotein IIb/IIIa inhibitors, whereas patients
in Canada more commonly received heparin.
Invasive cardiac procedures
In Canada and the US, high-risk patients had lower rates of car-
diac catheterization and catheterization within 48 h, and were
less likely to receive percutaneous coronary intervention than
moderate- and low-risk patients (Figure 1, Tables 4 and 5). High-
risk patients also had longer median times from presentation to
catheterization and percutaneous coronary intervention than
moderate- and low-risk patients (Table 6). Overall, rates of
catheterization, percutaneous coronary intervention and bypass
surgery were higher in the US. When restricting the patient pop-
ulation to only those presenting to a hospital with onsite cardiac
catheterization facilities, similar results were observed among the
US (n=78,886) and Canadian (n=845) patients, with high-risk
patients being least likely to undergo cardiac catheterization,
Pardoxical use of invasive cardiac procedures in NSTEMI
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TABLE 1
Baseline demographics and presenting characteristics by risk group for the United States and Canada
United States Canada
Low risk Moderate risk High risk Low risk Moderate risk High risk 
Variable (n=19,154) (n=20,456) (n=44,673) P (n=863) (n=764) (n=1072) P
Age (years) 51 (45, 57) 63 (56, 70) 77 (70, 83) <0.0001 54 (48, 60) 67 (59, 72) 76 (70, 82) <0.0001
Male sex 69.1 63.4 54.5 <0.0001 74.0 66.9 63.3 <0.0001
Heart rate (beats/min) 73 (64, 84) 77 (66, 89) 90 (76, 108) <0.0001 69 (60, 80) 75 (63, 88) 88 (74, 104) <0.0001
Systolic blood pressure (mmHg) 151 (133, 172) 148 (129, 169) 140 (119, 160) <0.0001 150 (133, 171) 150 (130, 171) 141 (122, 164) <0.0001
ST depression/transient ST elevation 31.4 44.8 56.1 <0.0001 11.9 23.3 48.2 <0.0001
Signs of congestive heart failure 4.2 9.6 36.7 <0.0001 5.7 13.7 31.2 <0.0001
on presentation*
Renal insufficiency† 6.4 9.4 18.2 <0.0001 2.1 3.8 11.2 <0.0001
Hypertension 59.7 67.8 72.8 <0.0001 44.3 51.7 62.0 <0.0001
Diabetes mellitus 24.6 32.3 36.3 <0.0001 18.7 27.1 35.3 <0.0001
Current/recent smoking 47.1 32.0 16.5 <0.0001 42.1 24.1 15.1 <0.0001
Dyslipidemia 47.5 52.4 44.2 <0.0001 47.7 46.6 45.1 0.50
Prior myocardial infarction 23.3 28.6 34.5 <0.0001 21.1 27.0 43.2 <0.0001
Percutaneous coronary intervention 20.7 24.1 20.5 <0.0001 12.2 15.2 12.8 0.18
Prior coronary artery bypass grafting 12.0 20.3 23.2 <0.0001 7.0 12.0 16.3 <0.0001
Prior stroke 4.3 7.9 14.8 <0.0001 2.6 8.5 15.2 <0.0001
Values are presented as percentages or median (25th and 75th percentiles) for age, heart rate and systolic blood pressure. *Defined as jugular venous distension,
rales, a third heart sound or pulmonary edema on initial chest x-ray documented by a physician on the initial history review and physical examination; †Defined as
creatinine >177 μmol/L, calculated creatinine clearance <0.5 mL/s or the need for chronic renal dialysis
10429_zia.qxd  19/10/2007  1:37 PM  Page 1075
catheterization within 48 h and percutaneous coronary interven-
tion (all P<0.001; data not shown).
Unadjusted in-hospital clinical outcomes
Rates of death, reinfarction and death or reinfarction were pro-
gressively higher from the low- and moderate- to high-risk groups
in both the US and Canada (Tables 7 and 8). Compared with the
US, mortality rates by risk category were slightly lower in
Canadian patients, but reinfarction rates were higher.
DISCUSSION
We performed an analysis of the contemporary treatment of US
and Canadian patients with NSTE ACS. Our study was unique, in
that it dealt specifically with NSTE ACS using a much larger
sample size than previous reports. In addition, our data were drawn
from an era in which a significant number of patients were being
treated after the emergence of evidence favouring an early inva-
sive strategy. Moreover, we have incorporated the impacts of risk
on choice of a management strategy in the real world. Our analy-
sis revealed a paradoxical relationship between risk and treatment.
Specifically, in both Canada and the US, the highest risk patients
with NSTE ACS were least likely to receive guideline-
recommended medical therapies and invasive cardiac procedures.
The lower use of glycoprotein IIb/IIIa inhibitors in these patients
can be explained, in part, by the lower rate of invasive cardiac pro-
cedures, because the greatest benefit of glycoprotein IIb/IIIa
inhibitor therapy is in the context of an invasive procedure (8).
Overall, catheterization and revascularization rates were higher in
the US than in Canada. These results suggest that resource avail-
ability does not appear to influence triage decision making for
NSTE ACS patients based on patient risk stratification.
Risk stratification
The differences observed in our analysis suggest that longstanding
treatment biases continue to limit the adoption of a risk stratifica-
tion approach to NSTE ACS management in the US and Canada.
While practice guidelines strongly advocate targeting aggressive
management approaches for patients with the highest expected
risk of mortality, studies have consistently shown that patients
with NSTE ACS and high-risk features, such as advanced age,
diabetes mellitus, signs of congestive heart failure and renal insuf-
ficiency, less commonly receive evidence-based medications and
less commonly undergo catheterization and revascularization
(13,26-28). However, early invasive management strategies have
been shown to have preserved benefit in these populations, so
Zia et al
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TABLE 3
Unadjusted OR and 95% CI for medication use by risk group
Medication Total, n Risk group OR (95% CI) P
Acetylsalicylic acid 78,700 Moderate versus low 0.83 (0.77–0.90) <0.0001
High versus low 0.57 (0.53–0.62) <0.0001
Glycoprotein IIb/IIIa Inhibitors 72,326 Moderate versus low 0.84 (0.80–0.88) <0.0001
High versus low 0.47 (0.45–0.50) <0.0001
Clopidogrel 82,132 Moderate versus low 0.92 (0.88–0.95) <0.0001
High versus low 0.66 (0.63–0.69 <0.0001
Any heparin 79,525 Moderate versus low 0.94 (0.89–1.00) 0.043
High versus low 0.69 (0.64–0.74) <0.0001
Intravenous or unfractionated heparin 79,525 Moderate versus low 0.95 (0.91–0.98) 0.004
High versus low 0.76 (0.73–0.80) <0.0001
Low-molecular-weight heparin 79,525 Moderate versus low 1.04 (1.00–1.08) 0.035




































United States Canada 
Figure 1) Rates of cardiac catheterization by risk group in the United
States and Canada
TABLE 2
Acute (<24 h) medications by risk group for the United States and Canada
United States Canada
Low risk Moderate risk High risk Low risk Moderate risk High risk
Medication (n=19,154) (n=20,456) (n=44,673) (n=863) (n=764) (n=1072)
Acetylsalicylic acid (%) 94.2 93.2 90.3 96.1 93.7 89.3
Glycoprotein IIb/IIIa inhibitor (%) 47.5 43.1 28.9 14.1 12.7 7.1
Clopidogrel (%) 46.1 44.5 36.2 35.5 35.2 30.2
Any heparin (%) 86.2 85.8 81.6 95.3 92.3 88.1
Unfractionated heparin (%) 54.2 53.1 47.3 40.8 40.1 39.7
Low-molecular-weight heparin (%) 38.8 39.8 40.4 54.5 52.2 48.2
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TABLE 4
In-hospital invasive cardiac procedures by risk group
United States Canada
Low risk Moderate risk High risk Low risk Moderate risk High risk
Procedure (n=19,154) (n=20,456) (n=44,673) (n=863) (n=764) (n=1072)
Cardiac catheterization (%) 76.2 74.2 53.2 63.5 58.1 40.5
Catheterization <48 h (%) 58.9 54.2 33.7 19.4 19.2 10.0
Percutaneous coronary intervention (%) 51.0 46.8 28.2 32.3 25.3 14.4
Percutaneous coronary intervention <48 h (%) 40.6 35.2 18.5 10.0 6.7 3.9
Coronary artery bypass grafting (%) 11.2 14.3 10.4 6.8 9.2 7.7
TABLE 5
Unadjusted OR and 95% CI for procedures by risk group
Procedure Total, n Risk group OR (95% CI) P
Diagnostic catheterization 81,915 Moderate versus low 0.89 (0.85–0.93) <0.0001
High versus low 0.42 (0.38–0.45) <0.0001
Catheterization within 48 h of arrival 78,552 Moderate versus low 0.81 (0.78–0.84 <0.0001
High versus low 0.37 (0.35–0.40) <0.0001
Percutaneous coronary intervention 71,519 Moderate versus low 0.83 (0.80–0.87) <0.0001
High versus low 0.42 (0.39–0.45) <0.0001
Percutaneous coronary intervention 70,095 Moderate versus low 0.77 (0.74–0.81) <0.0001
within 48 h of arrival High versus low 0.35 (0.32–0.37) <0.0001
Coronary artery bypass grafting 70,882 Moderate versus low 1.34 (1.24–1.44) <0.0001
High versus low 0.98 (0.89–1.07) 0.65
TABLE 6
Time to in-hospital invasive cardiac procedures by risk group
United States Canada†
Low risk Moderate risk High risk Low risk Moderate risk High risk 
Procedure (n=19,154) (n=20,456) (n=44,673) P (n=863) (n=764) (n=1072) P
Time to catheterization* (h) 22.7 (9.4, 43.3) 24.4 (11.5, 47.7) 34.3 (16.1, 65.0) <0.0001 96 (48, 144) 96 (48, 144) 120 (60, 168) 0.0002
Time to PCI* (h) 20.7 (6.0, 41.1) 22.5 (6.6, 45.8) 30.3 (11.9, 64.1) <0.0001 96 (48, 168) 120 (48, 168) 120 (48, 192) 0.21
Time to CABG* (h) 64.4 (39.5, 102.6) 69.9 (41.5, 110.6) 83.4 (45.6, 132.4) <0.0001 240 (168, 360) 300 (192, 432) 300 (216, 432) 0.31
*Values are presented as median (25th and 75th percentiles) for time to cardiac procedures; †Time to procedures in Canadian ACS registries were reported as days,
which were converted to hours for Canadian patients for this table. CABG Coronary artery bypass grafting; PCI Percutaneous coronary intervention
TABLE 7
In-hospital outcomes by risk group
United States Canada
Low risk Moderate risk High risk Low risk Moderate risk High risk
Event n=19,154 n=20,456 n=44,673 n=863 n=764 n=1072
Death (%) 0.9 1.8 7.8 0.5 0.9 6.2
Reinfarction (%) 2.2 2.6 3.7 5.6 6.4 7.3
Death or reinfarction (%) 2.9 4.1 10.5 5.9 7.2 11.3   
TABLE 8
Unadjusted OR and 95% CI for in-hospital outcomes by risk group
Event Total, n Risk group OR (95% CI) P
Death 73,594 Moderate versus low 2.08 (1.76–2.47) <0.0001
High versus low 8.57 (7.34–10.01) <0.0001
Postadmission infarction 72,631 Moderate versus low 1.16 (1.02–1.31) 0.0193
High versus low 1.58 (1.41–1.77) <0.0001
Death or myocardial infarction 72,837 Moderate versus low 1.40 (1.27–1.56) <0.0001
High versus low 3.50 (3.15–3.88) <0.0001
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safety concerns regarding the risks of invasive procedures in high-
risk patients may be counterbalanced by the benefits offered by
aggressive treatment strategies (29-31). It is possible that there
were additional comorbidities and contraindications for invasive
management that were not adequately accounted for in our analy-
sis, but consistent findings across multiple observational studies
have demonstrated that patients with NSTE ACS who are at the
highest risk of mortality and have the greatest potential benefit
from aggressive management are least likely to receive evidence-
based care.
Efficiency of invasive management practices
Availability of resources would be expected to influence decisions
regarding the triaging of patients with NSTE ACS to invasive car-
diac procedures in Canada, where access to catheterization and
revascularization is less available than in the US, such that higher-
risk patients would be preferentially triaged to invasive manage-
ment strategies (32). However, we have demonstrated that an
inverse relationship between patient risk status and likelihood of
undergoing catheterization and percutaneous coronary interven-
tion persists in both Canada and the US, which suggests that
treatment disparities for high-risk patients are not explained by
access to cardiac services or the availability of procedural facilities.
Similar findings from a prior analysis of cardiac catheterization
rates in patients with STEMI showed that the predicted risk of
severe coronary artery disease had no relationship to the frequency
of catheterization in both countries (21). Additionally, the preva-
lence of severe coronary disease identified during catheterization
after STEMI was similar in the US and Canada, but the higher fre-
quency of catheterization in the US led to a greater than twofold
higher rate of identification of severe coronary disease (20). Thus,
more aggressive patterns of catheterization in the US can likely
identify more patients with NSTE ACS who had severe coronary
artery disease and who would be expected to benefit from revascu-
larization, but the selective referral of low- to moderate-risk
patients for invasive procedures in both the US and Canada sug-
gests that the efficiency of invasive management strategies is not
ideal in either country. The observed outcome differences among
different risk groups verify that the risk model used in our study is
appropriate for our patient population. However, a cause-and-
effect relationship cannot be reliably made based on these
observed differences alone.
Limitations
There are several limitations to the present study. First, these
analyses are retrospective and based on observational data.
Second, site selection in CRUSADE and the Canadian ACS reg-
istries was not random or specifically population-based.
Furthermore, access to cardiac catheterization may be inherently
limited for those patients presenting to a hospital without these
facilities, and this might have impacted our findings. In an effort
to address this issue, secondary analyses were performed in just
those patients who presented to hospitals with on-site cardiac
catheterization; the findings were consistent with the overall
results. Third, we compared patients with unstable angina and
NSTEMI from CRUSADE with patients with NSTEMI from the
Canadian ACS registries as detailed in the methods, but approx-
imately 90% of patients in CRUSADE have positive cardiac
markers, so the comparison populations were similar (13).
Fourth, we used the PURSUIT model to risk-stratify our
patients, which has inferior prognostic calibration to other mod-
els in predicting in-hospital mortality. However, this model has
previously been shown to have good discriminatory performance
in predicting in-hospital mortality rates among the overall popu-
lation in the Canadian ACS I Registry (33). Fifth, reinfarction
rates were not adjudicated by a central committee, and hence,
may be under-reported. Sixth, the objectives of our analysis were
not to compare treatments and outcomes between the US and
Canada, so we did not assess the impact of treatment differences
between the countries on patient outcomes. Seventh, outcome
data are limited to in-hospital events and do not evaluate longer-
term differences in outcomes. Eighth, 3814 (4.3%) and 44
(1.6%) patients were excluded from the CRUSADE and
Canadian ACS registries, respectively, due to missing data that
precluded risk status classification. Ninth, because increasing age
is a major contributor to the risk status and is often accompanied
by comorbidities and different functional capacity and quality of
life expectations that were not adequately captured by our case
report forms, we may be overestimating the number of patients in
the higher-risk group who were truly eligible for cardiac catheter-
ization. Finally, the time frames for the generation of both the
US and Canadian data were not entirely congruous and over-
lapped with the initial publication of the ACC/AHA guidelines
and Canadian recommendations for NSTE ACS, as well as their
subsequent updates in 2002 (7-10). It is therefore possible that
changes in practice due to the ACC/AHA guidelines and
Canadian recommendations were not fully captured by our
analysis.
CONCLUSIONS
More appropriate triage decision making is needed to improve the
use of guideline-recommended medical therapies and invasive car-
diac procedures in patients with NSTE ACS in the US and
Canada. Because improved adherence to guidelines has been
shown to be associated with lower mortality in this population,
increased use of guidelines recommendations in patients with
high-risk NSTE ACS is expected to have a significant impact on
ACS mortality rates in both the US and Canada (6,34).
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